HEPA News and Press, Hepion Pharmaceuticals Inc. From 10/18/19

Point Roberts, WA and Delta, BC - October 18, 2019 (Investorideas.com Newswire) a global news source and leading investor resource announces its weekly roundup of stocks added to its global stock directories in cannabis, biotech, eSport, defense and mining. The newest cannabis, defense and m...

Gildan Activewear (NYSE: GIL )  -34%  on Q3 preliminary results . More news on: Gildan Activewear Inc., Hepion Pharmaceuticals, Inc., L Brands, Inc., Stocks on the move, Read more ...

Gainers:  Hepion Pharmaceuticals (NASDAQ: HEPA ) +64% . Assembly Biosciences (NASDAQ: ASMB ) +41% . Professional Diversity Network (NASDAQ: IPDN ) +31% . Synthesis Energy Systems (NASDAQ: SES ) +23% . Limelight Networks (NASDAQ: LLNW ) +21% . CARBO Ceramics (NYSE: CRR ) +21% . E...

Can-Fite BioPharma (NYSEMKT: CANF ) +75%  and Gebro Pharma on development & commercialization of phase III drug candidate Piclidenoson in the treatment of Rheumatoid Arthritis. More news on: Can-Fite BioPharma Ltd., Hepion Pharmaceuticals, Inc., Cronos Group Inc., Stocks on the...

Thinly traded nano cap Hepion Pharmaceuticals (NASDAQ: HEPA ) is up  80%  premarket on increased volume in reaction to preclinical data on NASH candidate CRV431. The data were just published in the Journal of Pharmacology and Experimental Therapeutics . More news on: Hepion ...

CRV431 Decreased Liver Fibrosis and Tumor Burden in Experimental Models EDISON, NJ / ACCESSWIRE / October 16, 2019 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising fro...

Market Assessment In Q2/2019, Hepion Pharmaceuticals (HEPA) started a “new clinical life” with a name change from ContraVir Pharmaceuticals (CTRV). It also streamlined its clinical program with a focus on CRV431 in NASH and Hepatitis B infection. The timeline revealed by the ...

EDISON, NJ / ACCESSWIRE / October 10, 2019 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis ("NASH") and chronic viral infection, today...

NEW YORK, Oct. 10, 2019 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, is pleased to announce that Jam...

Collectively, Company's Senior Management Team Has More Than 100 Years of Cyclophilin Experience EDISON, NJ / ACCESSWIRE / October 3, 2019 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liv...